MTOR and ovarian cancer: It is a prooxidant molecule [7, 8] that inhibits the mammalian target of rapamycin (mTOR)C1/2 in glioblastoma multiforme [9], induces microtubule-associated protein 1A/1B light chain 3B- (LC3-) mediated anoikis, and inhibits autophagy in ovarian cancer [10].